CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,328,475 | -1.7% | 29,268 | +21.5% | 0.07% | 0.0% |
| Q2 2023 | $1,352,076 | +4.5% | 24,084 | -15.8% | 0.07% | -8.8% |
| Q1 2023 | $1,293,985 | +264.5% | 28,609 | +227.6% | 0.08% | +247.8% |
| Q4 2022 | $354,996 | -36.2% | 8,733 | +2.7% | 0.02% | -42.5% |
| Q3 2022 | $556,000 | +12.3% | 8,506 | +4.5% | 0.04% | +29.0% |
| Q2 2022 | $495,000 | -10.2% | 8,142 | -7.2% | 0.03% | +34.8% |
| Q1 2022 | $551,000 | – | 8,771 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |